Strategic Partnerships to Potentially Extend Commercial Reach
Strategic partnership for the development and commercialization of MicroPine
Potential milestone payments and reimbursed development costs:
(Reimbursed development costs associated with Phase 3 CHAPERONE trail to begin immediately)
Royalties on gross profit: mid-single digit to mid-teen percentages.
Territory: US and Canada
US impacted population with high myopia estimated at approximately 3M
Strategic partnership for the development of all MAP™ products
Equity stake in Eyenovia at the IPO
Potential reimbursed development costs
Potential royalties and supply agreement
Territory: Asia excluding markets sublicensed to Arctic Vision
Our MAP™ technology, delivered with the Optejet® dispenser, is covered by multiple international patents and may provide additional intellectual property protection as well as a superior way of delivering your ophthalmic topical medication. We have the expertise to with you to develop your product from phase II to approval with both efficiency and speed.
If your medication could benefit from any of the features that our technology makes possible, please contact us for an introductory discussion. Some of these features may include: